Anti-Idiotypic Antibodies for Controlled Reversal of Anti-CD3 Lymphodepletion

Researchers at Stanford have developed anti-idiotypic antibodies that reverse anti-CD3 monoclonal antibody therapy, giving clinicians control over the depth and timing of T cell depletion before adoptive cell therapy. These reversal agents bind the anti-CD3 antibody itself and block its engagement of CD3, allowing residual circulating antibody to be neutralized on demand. Two lead agents bind teplizumab with high affinity, block teplizumab binding to human peripheral blood mononuclear cells, and inhibit teplizumab-driven T cell activation in a concentration-dependent manner. The two agents recognize distinct epitopes on teplizumab and differ in the extent of blockade they achieve, so the degree of reversal can be tuned.

In mouse studies, a single dose of either agent accelerated teplizumab clearance from serum, and in a humanized graft-versus-host disease model the agents restored human cell engraftment that teplizumab had suppressed. This capability addresses a core limitation of anti-CD3 therapy: serum levels vary widely between patients and circulating antibody can persist for days to weeks, producing inconsistent depletion and leaving residual antibody that destroys infused cell products. By clearing that antibody at a defined point, the reversal agents open a therapeutic window for pairing anti-CD3 lymphodepletion with regulatory T cell and other engineered T cell therapies.